Eton Pharmaceuticals (NASDAQ:ETON) Research Coverage Started at B. Riley

Stock analysts at B. Riley started coverage on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a report issued on Thursday, The Fly reports. The brokerage set a “buy” rating on the stock.

Other analysts also recently issued research reports about the company. TheStreet downgraded Eton Pharmaceuticals from a “c-” rating to a “d+” rating in a research note on Monday, August 9th. HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of Eton Pharmaceuticals in a research note on Tuesday, September 7th.

ETON stock opened at $5.43 on Thursday. The business’s 50-day moving average price is $4.95 and its two-hundred day moving average price is $6.23. The company has a current ratio of 9.36, a quick ratio of 8.96 and a debt-to-equity ratio of 0.29. The firm has a market cap of $133.58 million, a PE ratio of -10.44 and a beta of 1.22. Eton Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $10.30.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Sunday, August 15th. The company reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.04. The business had revenue of $3.07 million for the quarter, compared to the consensus estimate of $3.83 million. On average, analysts forecast that Eton Pharmaceuticals will post 0.34 earnings per share for the current year.

In other news, major shareholder Opaleye Management Inc. sold 34,101 shares of the business’s stock in a transaction that occurred on Monday, October 11th. The stock was sold at an average price of $5.01, for a total transaction of $170,846.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders have sold 526,793 shares of company stock valued at $3,002,106. Corporate insiders own 9.71% of the company’s stock.

Large investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD bought a new stake in shares of Eton Pharmaceuticals in the second quarter valued at approximately $1,342,000. Vanguard Group Inc. boosted its stake in shares of Eton Pharmaceuticals by 21.2% in the second quarter. Vanguard Group Inc. now owns 861,540 shares of the company’s stock valued at $5,307,000 after buying an additional 150,681 shares during the period. Millennium Management LLC bought a new stake in shares of Eton Pharmaceuticals in the second quarter valued at approximately $831,000. Marshall Wace LLP bought a new stake in shares of Eton Pharmaceuticals in the second quarter valued at approximately $523,000. Finally, Tibra Equities Europe Ltd bought a new stake in shares of Eton Pharmaceuticals in the second quarter valued at approximately $319,000. Institutional investors own 27.81% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection.

Further Reading: What is the CBOE Russell 2000® Volatility Index?

The Fly logo

Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.